Functional Characterization of a Novel Variant of the Thyroid Hormone Receptor Alpha in a Child with Developmental Delay and Abnormal Thyroid Function.
Véronique Caron, Katherine Bonnycastle, Agathe Rio, Lyne Chiniara, Mélanie Henderson, Guy Van Vliet, André Tremblay, Fabien Magne
{"title":"Functional Characterization of a Novel Variant of the Thyroid Hormone Receptor Alpha in a Child with Developmental Delay and Abnormal Thyroid Function.","authors":"Véronique Caron, Katherine Bonnycastle, Agathe Rio, Lyne Chiniara, Mélanie Henderson, Guy Van Vliet, André Tremblay, Fabien Magne","doi":"10.1177/10507256261490862","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Resistance to thyroid hormone α (RTHα) is a rare disorder caused by pathogenic <i>THRA</i> variants. We investigated the molecular basis of RTHα in a child with developmental delay, dysmorphic features, and a suggestive biochemical profile.</p><p><strong>Methods: </strong>Whole-exome sequencing identified a <i>de novo THRA</i> variant. Cell-based transcriptional assays assessed thyroid hormone responsiveness, coactivator dependence, and dominant-negative activity.</p><p><strong>Results: </strong>A novel heterozygous frameshift variant, c.1125_1132dup (p.Gly378Alafs*2), truncating the ligand-binding domain, was identified. The mutant receptor showed markedly impaired responses to triiodothyronine (T3) and TRIAC. CBP/p300 and PGC1α failed to activate the variant, supporting loss of function. Co-expression studies demonstrated strong inhibition of wild-type <i>THRA</i> activity that was not rescued by high T3 concentrations, indicating a potent dominant-negative effect. Disruption of DNA binding abolished this interference, showing that DNA occupancy is required.</p><p><strong>Conclusions: </strong>These findings expand the spectrum of pathogenic <i>THRA</i> variants and provide new insight into transcriptional repression in RTHα.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"1267-1274"},"PeriodicalIF":6.6000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10507256261490862","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Resistance to thyroid hormone α (RTHα) is a rare disorder caused by pathogenic THRA variants. We investigated the molecular basis of RTHα in a child with developmental delay, dysmorphic features, and a suggestive biochemical profile.
Methods: Whole-exome sequencing identified a de novo THRA variant. Cell-based transcriptional assays assessed thyroid hormone responsiveness, coactivator dependence, and dominant-negative activity.
Results: A novel heterozygous frameshift variant, c.1125_1132dup (p.Gly378Alafs*2), truncating the ligand-binding domain, was identified. The mutant receptor showed markedly impaired responses to triiodothyronine (T3) and TRIAC. CBP/p300 and PGC1α failed to activate the variant, supporting loss of function. Co-expression studies demonstrated strong inhibition of wild-type THRA activity that was not rescued by high T3 concentrations, indicating a potent dominant-negative effect. Disruption of DNA binding abolished this interference, showing that DNA occupancy is required.
Conclusions: These findings expand the spectrum of pathogenic THRA variants and provide new insight into transcriptional repression in RTHα.
期刊介绍:
This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes.
Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.